Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082758 | 0.91 | DGAT1 (0.34) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL3313603 | 0.87 | NPC1 (0.40) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL8664242 | 0.87 | DGAT1 (0.34) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL26917090 | 0.86 | DGAT1 (0.35) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL5661987 | 0.86 | DGAT1 (0.36) | SMN1; SMN2DGAT1NPC1MAPT | |
| SCHEMBL31305763 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2KLKB1DGAT1NPC1MAPT | |
| SCHEMBL6171967 | 0.85 | DGAT1 (0.34) | SMN1; SMN2KLKB1DGAT1NPC1MAPT | |
| SCHEMBL27265900 | 0.84 | ALDH1A1 (0.40) | SMN1; SMN2DGAT1NPC1RAB9A | |
| SCHEMBL22645106 | 0.83 | DGAT1 (0.39) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL1858968 | 0.83 | DGAT1 (0.38) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4562002-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024023330-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | NODUS ONCOLOGY LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| EP-3374359-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017080979-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-05-18 | — | — | WO | disclosed |
| EP-2627650-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |